Advertisement

Der Hautarzt

, Volume 63, Issue 3, pp 184–191 | Cite as

„Stiefkind“ Nagelpsoriasis

Pathogenese, Diagnostik, Therapie
  • C. Kahl
  • B. Hansen
  • K. Reich
Leitthema

Zusammenfassung

Etwa 50% aller Psoriasispatienten weisen eine Nagelbeteiligung als klinisches Korrelat einer psoriatischen Entzündung der Nagelmatrix und/oder des Nagelbettes auf. Die häufigsten Zeichen einer Nagelpsoriasis sind Tüpfel und distale Onycholysen. Der derzeit am häufigsten eingesetzte Score zur Erfassung der Schwere einer Nagelbeteiligung ist der Nail Psoriasis Severity Index (NAPSI). Allerdings werden patientenbezogene Symptome in diesem Index nicht berücksichtigt, obwohl mehr als die Hälfte der Betroffenen zum Teil unter deutlichen physischen und psychischen Einschränkungen leiden. Auffällig ist der Zusammenhang zwischen einer Nagelpsoriasis und dem Risiko einer Gelenkbeteiligung. Die Prävalenz einer Nagelpsoriasis beträgt bei Patienten mit Psoriasisarthritis etwa 70%. Ursächlich für diese Wechselbeziehung scheint der über die Fasern der Strecksehne vermittelte enge anatomische Kontakt zwischen Nagelapparat und distalem Interphalangealgelenk zu sein. Eine Enthesitis kann damit in der Erkrankung des Nagels sichtbar werden. Nagelveränderungen werden aktuell im Therapiemanagement oft nicht ausreichend berücksichtigt. Es gibt nur begrenzte Evidenz zur Wirksamkeit lokaler Therapieformen, mittlerweile liegen aber gute Daten insbesondere zur Wirksamkeit der Biologics und neuerdings auch zu Methotrexat in der Behandlung der Nagelpsoriasis vor.

Schlüsselwörter

Nagelpsoriasis Pathogenese Diagnostik Therapie Psoriasisarthritis 

Nail psoriasis—an ignored disorder

Pathogenesis, diagnosis and therapy

Abstract

Approximately 50% of all patients with psoriasis develop characteristic nail changes as a clinical correlate of psoriatic inflammation of the nail matrix and/or nail bed. The most frequent signs of nail psoriasis are pitting and distal onycholysis. The most commonly used score to assess the severity of nail involvement at present is the Nail Psoriasis Severity Index (NAPSI). Although more than half of affected patients experience a significant physical and mental impairment, this index does not include patient-reported symptoms. There is a striking association between nail psoriasis and a higher risk of psoriatic arthritis with a prevalence of nail involvement among patients with psoriatic arthritis as high as 70%. A possible explanation is the close anatomical link between the nail apparatus and the distal interphalangeal joint; enthesitis of the latter is carried by fibers to the nail and becomes clinically visible as nail psoriasis. Nail involvement is not adequately reflected in current concepts of disease management. There is limited evidence for the efficacy of topical therapies in nail psoriasis. A number of large studies document an improvement of nail psoriasis in response to biologics and, more recently, also to methotrexate.

Keywords

Nail psoriasis Pathogenesis Diagnosis Therapy Psoriatic arthritis 

Notes

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Prof. Kristian Reich wirkte an klinischen Studien mit und arbeitete als Berater, Referent und Beiratsmitglied von Abbott, AMGEN, Biogen-Idec, Celgene, Centocor, Forward Pharma, Galderma, Janssen-Cilag, LEO Pharma, Medac, MSD, Novartis und Pfizer. Dr. Christina Kahl hat an klinischen Studien, gesponsert von Abbott, AMGEN, Biogen-Idec, Celgene, Centocor, Forward Pharma, Galderma, Janssen-Cilag, LEO Pharma, MSD, Novartis und Pfizer, mitgewirkt. Für Bente Hansen liegt kein Interessenkonflikt vor.

Literatur

  1. 1.
    Augustin M, Krüger K, Radtke MA et al (2008) Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 216(4):366–372PubMedCrossRefGoogle Scholar
  2. 2.
    Augustin M, Reich K, Blome C et al (2010) Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 163(3):580–585PubMedCrossRefGoogle Scholar
  3. 3.
    Baran R (2010) The burden of nail psoriasis: an introduction. Dermatology 221(Suppl 1):1–5PubMedCrossRefGoogle Scholar
  4. 4.
    De Berker DA, Lawrence CM (1998) A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol 138(1):90–95CrossRefGoogle Scholar
  5. 5.
    De Jong EM, Seegers BA, Gulinck MK et al (1996) Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 193(4):300–303CrossRefGoogle Scholar
  6. 6.
    Fawcett RS, Linford S, Stulberg DL (2004) Nail abnormalities: clues to systemic disease. Am Fam Physician 69(6):1417–1424PubMedGoogle Scholar
  7. 7.
    Gisondi P, Tinazzi I, El-Dalati G et al (2008) Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. Ann Rheum Dis 67(1):26–30PubMedCrossRefGoogle Scholar
  8. 8.
    Gregoriou S, Kalogeromitros D, Kosionis N et al (2008) Treatment options for nail psoriasis. Expert Rev Dermatol 3:339–344CrossRefGoogle Scholar
  9. 9.
    Gümüşel M, Özdemir M, Mevlitoğlu I, Bodur S (2011) Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study. J Eur Acad Dermatol Venereol 25(9):1080–1084PubMedCrossRefGoogle Scholar
  10. 10.
    Hamm H (2005) Erkrankungen der Nägel. In: Braun-Falco O, Plewig G, Wolff HH et al (Hrsg) Dermatologie und Venerologie. Springer, Berlin, S 955Google Scholar
  11. 11.
    Jiaravuthisan MM, Sasseville D, Vender RB et al (2007) Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 57(1):1–27PubMedCrossRefGoogle Scholar
  12. 12.
    Lawry M (2007) Biologic therapy and nail psoriasis. Dermatol Ther 20(1):60–67PubMedCrossRefGoogle Scholar
  13. 13.
    Luger TA, Barker J, Lambert J et al (2009) Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 23(8):896–904PubMedCrossRefGoogle Scholar
  14. 14.
    Márquez Balbás G, Sánchez Regaña M, Umbert Millet P (2009) Tacalcitol ointment for the treatment of nail psoriasis. J Dermatolog Treat 20(5):308–310CrossRefGoogle Scholar
  15. 15.
    McGonagle D, Lories RJ, Tan AL, Benjamin M (2007) The concept of a „synovio-entheseal complex“ and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 56(8):2482–2491PubMedCrossRefGoogle Scholar
  16. 16.
    McGonagle D, Marzo-Ortega H, Benjamin M, Emery P (2003) Report on the Second international Enthesitis Workshop. Arthritis Rheum 48(4):896–905PubMedCrossRefGoogle Scholar
  17. 17.
    McGonagle D, Palmou Fontana N, Tan AL, Benjamin M (2010) Nailing down the genetic and immunological basis for psoriatic disease. Dermatology 221(Suppl 1):15–22PubMedCrossRefGoogle Scholar
  18. 18.
    Mrowietz U, Kragballe K, Reich K et al (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303(1):1–10PubMedCrossRefGoogle Scholar
  19. 19.
    Oram Y, Karincaoğlu Y, Koyuncu E, Kaharaman F (2010) Pulsed dye laser in the treatment of nail psoriasis. Dermatol Surg 36(3):377–381PubMedCrossRefGoogle Scholar
  20. 20.
    Ortonne JP, Baran R, Corvest M et al (2010) Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol 24(1):22–27PubMedCrossRefGoogle Scholar
  21. 21.
    Raychaudhuri SP, Jiang WY, Raychaudhuri SK (2008) Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 172(4):961–971PubMedCrossRefGoogle Scholar
  22. 22.
    Reich K, Krüger K, Mössner R, Augustin M (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160(5):1040–1047PubMedCrossRefGoogle Scholar
  23. 23.
    Reich K, Langley RG, Papp KA et al (2011) A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 365(17):1586–1596PubMedCrossRefGoogle Scholar
  24. 24.
    Rich P, Griffiths CE, Reich K et al (2008) Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 58(2):224–231PubMedCrossRefGoogle Scholar
  25. 25.
    Rich P et al (2008) Improvement in nail psoriasis with ustekinumab, a new anti-IL-12/23 P40 monoclonal antibody: results from a phase 3 trial (PHOENIX 1). EADV Abstract FP1007Google Scholar
  26. 26.
    Rigopoulos D, Korfitis C, Gregoriou S, Katsambas AD (2008) Infliximab in dermatological treatment: beyond psoriasis. Expert Opin Biol Ther 8(1):123–133PubMedCrossRefGoogle Scholar
  27. 27.
    Saleem K, Azim W (2008) Treatment of nail psoriasis with a modified regimen of steroid injections. J Coll Physicians Surg Pak 18(2):78–81PubMedGoogle Scholar
  28. 28.
    Saraceno R, Bianchi L, Pietroleonardo L (2008) Remission and time of resolution of nail psoriasis: a comparison among antitumor necrosis factor-alpha inhibitors. Br J Dermatol 159(6):1418, P47Google Scholar
  29. 29.
    Scher RK, Stiller M, Zhu YI (2001) Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 68(5):355–358PubMedGoogle Scholar
  30. 30.
    Tan AL, Benjamin M, Toumi H et al (2007) The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis–a high-resolution MRI and histological study. Rheumatology (Oxford) 46(2):253–256Google Scholar
  31. 31.
    Thaçi D, Ortonne JP, Chimenti S et al (2010) A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 163(2):402–411PubMedCrossRefGoogle Scholar
  32. 32.
    Tosti A, Piraccini BM, Cameli N et al (1998) Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 139(4):655–659PubMedCrossRefGoogle Scholar
  33. 33.
    Tosti A, Ricotti C, Romanelli P et al (2009) Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 145(3):269–271PubMedCrossRefGoogle Scholar
  34. 34.
    Tzung TY, Chen CY, Yang CY et al (2008) Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol 88(3):279–280PubMedGoogle Scholar
  35. 35.
    Van den Bosch F, Manger B, Goupille P et al (2010) Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 69(2):394–399CrossRefGoogle Scholar
  36. 36.
    Williamson L, Dalbeth N, Dockerty JL et al (2004) Extended report: nail disease in psoriatic arthritis – clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 43(6):790–794Google Scholar
  37. 37.
    Wilson FC, Icen M, Crowson CS et al (2009) Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 61(2):233–239PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  1. 1.Dermatologikum HamburgHamburgDeutschland

Personalised recommendations